Verrica Deferred Long Term Liab from 2010 to 2024
| VRCA Stock | USD 1.24 0.13 11.71% |
Deferred Long Term Liabilities | First Reported 2010-12-31 | Previous Quarter 90 K | Current Value 80 K | Quarterly Volatility 5.6 K |
Check Verrica Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Verrica Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 605.9 K, Interest Expense of 4.2 M or Selling General Administrative of 17.5 M, as well as many indicators such as Price To Sales Ratio of 68.01, Dividend Yield of 0.0 or PTB Ratio of 17.63. Verrica financial statements analysis is a perfect complement when working with Verrica Pharmaceuticals Valuation or Volatility modules.
Verrica | Deferred Long Term Liab |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Verrica Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verrica Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verrica Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verrica Pharmaceuticals Stock:Check out the analysis of Verrica Pharmaceuticals Correlation against competitors. For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verrica Pharmaceuticals. If investors know Verrica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verrica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.84) | Revenue Per Share 0.198 | Quarterly Revenue Growth 27.445 | Return On Assets (0.71) | Return On Equity (20.60) |
The market value of Verrica Pharmaceuticals is measured differently than its book value, which is the value of Verrica that is recorded on the company's balance sheet. Investors also form their own opinion of Verrica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Verrica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verrica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Verrica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verrica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Verrica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verrica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.